Shenzhen Injoinic Technology (SH:688209) 财联社·2026-02-13 11:56Core Viewpoint - The China Securities Regulatory Commission (CSRC) has initiated an investigation into Shenzhen Yingjixin Technology Co., Ltd. for misleading statements related to information disclosure on January 6, 2026, regarding their brain-machine interface products [1]. Group 1: Incident Overview - On January 6, an investor inquired about the company's progress in brain signal acquisition technology. Yingjixin responded by highlighting their IPA1299 chip, which is designed for high-precision measurement of biological electrical signals and is suitable for brain-machine interface applications [2]. - Following this response, the Shanghai Stock Exchange issued a regulatory letter to Yingjixin regarding the content of their reply on the E-interaction platform [2]. Group 2: Product Details - On January 7, Yingjixin announced that the IPA1299 chip is an 8-channel, low-noise, 24-bit ADC primarily used for EEG, ECG, and EMG applications. It is designed for high-precision signal acquisition and is applicable in non-invasive brain-machine interface scenarios [3]. - The company noted that the IPA1299 is still in the market cultivation phase for non-invasive brain-machine interfaces and has not yet achieved significant sales or impacted the company's financial performance [3]. Group 3: Market Reaction - Despite the announcement clarifying the situation, Yingjixin's stock price opened over 9% higher on January 7, closing at 22.48 yuan per share, a 4.51% increase [4]. Group 4: Regulatory Actions - The Shanghai Stock Exchange's Sci-Tech Innovation Board issued a regulatory warning to Yingjixin and its then Secretary of the Board, Wu Renchao, for the misleading information [6].